Basis of Presentation (Tables)

9 Months Ended

Dec. 01, 2018

Basis of Presentation

Schedule of revenues

	For the thirteen week period		For the thirty-nine week period
In thousands	ended December 1, 2018		ended December 1, 2018
Retail Pharmacy segment:
Pharmacy sales	$	2,664,200	$	7,803,395
Front end sales		1,276,621		3,873,830
Other revenue		35,898		108,771
Total Retail Pharmacy segment	$	3,976,719	$	11,785,996
Pharmacy Services segment		1,525,837		4,630,410
Intersegment elimination		(52,496)		(156,494)
Total revenue	$	5,450,060	$	16,259,912

Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet

	Impact of Change in Accounting Policy
	As Reported				Adjusted
In thousands	March 3, 2018		Adjustments		March 4, 2018
Condensed Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100	$	(57,897)	$	1,811,203
Inventories, net		1,799,539		51,121		1,850,660
Deferred tax assets		594,019		(1,772)		592,247
Total assets		8,989,327		(8,548)		8,980,779
Accumulated deficit		(4,282,471)		(8,548)		(4,291,019)
Total shareholders' equity		1,601,010		(8,548)		1,592,462